Experience

LB Pharmaceuticals Announces $285 Million Upsized IPO

September 12, 2025

Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).

Read more

Related contacts

Brandon W. Fenn
Partner, New York
Div Gupta
Partner, New York
Marc Recht
Partner, Boston
Minkyu Park
Special Counsel, New York
Denny Xu
Associate, Boston
Danbi Kim
Associate, Boston
Ariane A. Andrade
Partner, Chicago
Nathaniel Hearn Jr.
Associate, Chicago
Karun Ahuja
Special Counsel, Chicago
Brandon Lefebvre
Quantitative Analyst, Boston
Stephanie Gentile
Partner, New York
Austin Holt
Partner, Santa Monica
Eileen Marshall
Partner, Washington, DC
Phil Mitchell
Partner, New York
Gerard O'Shea
Partner, New York
David Peinsipp
Partner, San Francisco
Ryan Vann
Partner, Chicago
Francis Wheeler
Senior Counsel, Colorado
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Jessica Koffel
Special Counsel, Brussels
Rebecca Ross
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Chelsea Braun
Associate, Boston
Cara Buchicchio
Associate, New York
David Dalton
Associate, Santa Monica
Vince Flynn
Associate, San Diego
Virat Gupta
Associate, Washington, DC
Wyatt Kernell
Associate, Colorado
Allison Kutner
Associate, New York
Brenna McGuire
Associate, Washington, DC
Sarah Miller
Associate, New York
Jayne M. Munger
Associate, New York
Miles Patton
Associate, New York
Alla Kagan
Paralegal Specialist, San Diego
Cathy Rude
Paralegal Specialist, Boston
Jake Ironfield
Transactional Quantitative Analyst, New York
Brian Mitchell
Transactional Quantitative Analyst, San Diego

Related Practices & Industries

Tourmaline Bio Enters Into Agreement to be Acquired by Novartis

September 9, 2025

Read more

Related contacts

Bill Sorabella
Partner, New York
Brandon W. Fenn
Partner, New York
Natalie D. Vernon
Associate, Colorado
Sangitha Palaniappa
Associate, Palo Alto
Katherine Denby
Special Counsel, Washington, DC
Pengli Li
Associate, Boston
Nyron J. Persaud
Partner, New York
Megan Browdie
Partner, Washington, DC
Anne Luquette
Associate, San Francisco
Brittany Sanok
Associate, New York
Annie Froehlich
Partner, Washington, DC
Stephanie Gentile
Partner, New York
Austin Holt
Partner, Santa Monica
Christopher Kimball
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Carly Mitchell
Partner, Washington, DC
Phil Mitchell
Partner, New York
Ryan Montgomery
Partner, Boston
John Paul Oleksiuk
Partner, New York
Alan W. Tamarelli
Partner, New York
Dr. Michael Tuscan
Partner, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
J. Brian Stalter
Special Counsel, New York

Related Practices & Industries

Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical

March 17, 2025

Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.

Read more

Related contacts

Bill Roegge
Partner, New York
Kenneth Krisko
Partner, Reston
Simon Amies
Partner, London
Rita Sobral
Special Counsel, London
Stephanie Parker Palmer
Special Counsel, Reston
Michael Bergmann
Partner, Washington, DC
Brandon W. Fenn
Partner, New York
Eileen Marshall
Partner, Washington, DC
Jeremy Morrison
Partner, Washington, DC
Stella Sarma
Partner, Brussels
Ryan Vann
Partner, Chicago
Natasha Leskovsek
Of Counsel, Washington, DC
Matthew Choy
Associate, New York
Kyle Hess
Associate, New York
Katie Kaufman
Associate, Boston
Edward (Teddy) Nimetz
Associate, New York
Alexandra Paterson
Associate, London
Joseph Perry
Associate, Reston

Related Practices & Industries

Enavate Sciences Co-Leads Normunity’s $75 Million Series B

January 13, 2025

Cooley advised Enavate Sciences, a top investment firm, as the co-lead investor in the $75 million Series B financing round of Normunity, a biotechnology company creating novel anticancer therapies. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.

Related contacts

Marc Recht
Partner, Boston
Brandon W. Fenn
Partner, New York
Barry Kuang
Associate, Boston
Liz Gold
Associate, New York
Stephanie Gentile
Partner, New York

Related Practices & Industries

Windward Bio Closes $200 Million Series A

January 10, 2025

Cooley advised Windward Bio, a clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases, on its $200 million Series A financing round. Partners Brandon Fenn and Ryan Sansom led the Cooley team advising Windward Bio.

Related contacts

Brandon W. Fenn
Partner, New York
Ryan Sansom
Partner, Boston
Alex Abelson
Associate, New York

Related Practices & Industries

View more

Admissions and credentials

New York